Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27654 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Thomas L Sutton und 6 weiteren Autor:innen. Beteiligte Einrichtung: OHSU Department of Surgery, Division of Surgical Oncology, Knight Cancer Institute, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Imatinib Mesylate, Antineoplastic Agents, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: NCI NIH HHS, U.S. Department of Veterans Affairs.
Abstract (Originalsprache)
Introduction
Patients with high‐risk resected gastrointestinal stromal tumors (GIST) receiving adjuvant imatinib have improved recurrence‐free survival (RFS), however whether a complete cytocidal effect exists is unknown. We investigated this using a normalized recurrence timeline measured from end of oncologic treatment (EOOT), defined as the later of resection or end of adjuvant therapy.
Methods
We reviewed patients with resected high‐risk GIST at our cancer center from 2003 to 2018. RFS (measured from resection and EOOT), overall survival (OS), and time to imatinib resistance (TTIR) were analyzed using Kaplan‐Meier analysis and multivariable Cox proportional hazards modeling. The performance of the Memorial Sloan Kettering (MSK) GIST nomogram was assessed.
Results
We identified 86 patients with high‐risk GIST with a median 106 months of postsurgical follow‐up. One‐third ( n = 29; 34%) did not receive adjuvant imatinib, while 57 (66%) did for a median of 3 years. The MSK nomogram‐predicted 5‐year RFS for patients receiving adjuvant imatinib was similar to those who did not (29% vs. 31%, p = 0.64). When RFS was measured from EOOT, the MSK‐predicted RFS was independently associated with EOOT RFS (hazard ratio 0.22, p = 0.02), while adjuvant imatinib receipt and duration were not. Neither receipt nor duration of adjuvant imatinib were associated with TTIR or OS (all p > 0.05).
Conclusions
Treatment with adjuvant imatinib delays, but does not clearly impact ultimate recurrence, TTIR, or OS, suggesting many patients with high‐risk GIST may receive adjuvant imatinib unnecessarily. Additional studies are needed to establish the benefit of adjuvant therapy versus initiating therapy at first radiographic recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- OHSU Department of Surgery, Division of Surgical Oncology, Knight Cancer Institute, Portland, Oregon, USA.
- Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA.
- OHSU Department of Pathology, Knight Cancer Institute, Portland, Oregon, USA.
- OHSU Department of Medicine, Division of Hematology and Oncology, Knight Cancer Institute, Portland, Oregon, USA.
Förderung
- NCI NIH HHS
- U.S. Department of Veterans Affairs
Zitieren
APA
Sutton, T. L., Billingsley, K. G., Johnson, A. J., Corless, C. L., Blanke, C. D., Heinrich, M. C., & Mayo, S. C. (2024). Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27654
Vancouver
Sutton TL, Billingsley KG, Johnson AJ, Corless CL, Blanke CD, Heinrich MC, et al. Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27654
BibTeX
@article{Sutton2024,
author = {Sutton, Thomas L and Billingsley, Kevin G and Johnson, Alicia J and Corless, Christopher L and Blanke, Charles D and Heinrich, Michael C and Mayo, Skye C},
title = {Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27654}
}
EUVIMED